Douglas Oberhelman Elected to Lilly Board of...(sity and Easter Seals. About Lilly .....)
Navigation Links
| HOME >> BIOLOGY >> TECHNOLOGY |
Douglas Oberhelman Elected to Lilly Board of Directors
Date:10/20/2008
sity and Easter Seals.
About Lilly
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at http://www.lilly.com.
C-LLY
(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )
'/>"/>
| SOURCE Eli Lilly and Company Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Ambrx Appoints Douglas Axelrod Senior Vice President for Clinical Research and Development
2. Netsmart Technologies Selected by City and County of San Francisco to Provide Integrated Behavioral Healthcare Software System
3. NEXCORE Technology Selected to Manufacture New Endoscopic Cryotherapy Device
4. Fujitsu PalmSecure and HT Systems PatientSecure Selected by BayCare Health System to Protect Patient Confidentiality and Prevent Medical Identity Theft
5. JD Technologies, LLC Selected by FCT Ingenieurkeramik GmbH to Represent Their High Performance Ceramic Expertise In the United States
6. Animetrics Inc. Selected to Provide 3D Face Viewer Technology for United States Army Biometric Automated Toolset (BAT)
7. Schering-Plough Announces Closing of Planned Divestiture of Selected Animal Health Products
8. Sparta Systems Selected by Genzyme to Optimize Quality Assurance Processes with TrackWise
9. Cardium Selected for Inclusion in Russell Microcap Index
10. Governor Perdue Announces Georgia Selected as Home for New National Health Museum
11. Barry Ginsberg, M.D., Ph.D. Elected to Biodels Board of Directors
Post Your Comments:
Breaking Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 2Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years 3
[0] Lotus Pharmaceuticals, Inc. Appoints OTC Division Head[0] Martek Signs Sole-Source Supply Agreement with Fonterra[0] YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES[0] Hertz Annual Appeal for Adult Congenital Heart Disease Center At UCLA Passes $2-Million Mark in Funds Raised Over Ten Years
Other Biology Technology:Biotech Avoids Fall Out From Tough Quarter for Capital Markets 2Biotech Avoids Fall Out From Tough Quarter for Capital Markets 3Biotech Avoids Fall Out From Tough Quarter for Capital Markets 4Siemens Signs Multi-Year Agreement With Cleveland Clinic to Deploy Enterprise-Wide Cardiology PACS 2
Breaking Biology News(10 mins):Canna can: Ornamental eliminates pollutants from stormwater runoff 2New engineering institute to modify, develop technology for the global poor 2New engineering institute to modify, develop technology for the global poor 3Berkeley Lab researchers participate in Homeland Security study of subway airflow 2CIGNA Awarded State of Arizona Health Care Contract 54926 1CIGNA Awarded State of Arizona Health Care Contract 54926 2Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 1Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 2Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 3Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 4Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 5Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 6Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 7Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 8Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 9Newer Drug Beats Tamoxifen for Older Breast Cancer Patients 54919 1Newer Drug Beats Tamoxifen for Older Breast Cancer Patients 54919 2Newer Drug Beats Tamoxifen for Older Breast Cancer Patients 54919 3
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |